Clinical Trial Update: ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating two doses of AllerT for allergic rhinitis due to birch pollen; completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• AllerT

Snippet

Sponsor: Anergis | Conditions: Allergic Rhinitis | Phase 2 | Status: COMPLETED